stock downgrade
William Blair Downgrades Lucira Health to Market Perform
As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022.
Roche to Acquire GenMark Diagnostics for $1.8B
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
Oppenheimer Downgrades Invitae to Perform Rating
Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."
BTIG Downgrades Fulgent Genetics from Buy to Neutral
The investment bank said it expects demand for Fulgent's COVID-19 testing to decline over the next two years.
JP Morgan Rates Invitae Neutral
The investment bank also moved the company's stock price target to $45 from a prior target of $25 and noted several recent acquisitions by Invitae.
Jul 16, 2019
Qiagen Stock Downgraded to 'In Line' by Evercore ISI
Jul 9, 2019
Cowen Downgrades Myriad Genetics' Stock
Oct 25, 2018
LabCorp Downgraded by Canaccord Genuity
May 24, 2018
Vermillion Downgraded by Canaccord to Hold Rating
Dec 13, 2017
JP Morgan Downgrades Genomic Health to Underweight
Apr 19, 2017